sarclisa multiple myeloma news - Search News

Sarclisa, multiple myeloma and European Medicines Agency

GlobalData on MSN · 1d

EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade, plus Revlimid, plus dexamethasone (VRd) for treating newly diagnosed multiple myeloma (MM).

Business Insider · 2d

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ

Pharmabiz · 17h

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H

MarketWatch · 2d

Sanofi: Sarclisa Recommended for EU Approval by CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top

Sanofi wins appeal in spat with NICE over Sarclisa

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

GSK's ADC Blenrep delivers survival win against J&J's Darzalex

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

News Medical on MSN2d

Interactive atlas unveils immune changes in multiple myeloma

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

J&J bids to add smouldering myeloma to Darzalex label

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results